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Abstract
The aim of this study was to investigate the interaction of antiphospholipid antibodies (aPL) from two different
populations (patients with autoimmune or infectious disorders) with cardiolipin (CL) arranged in a defined bilayer.
L2-Glycoprotein I (L2GPI), an apolipoprotein that plays a critical role in the aPL binding to phospholipids, was quantified by
dot blot in purified IgG-aPL samples, further classified according to apparent avidity to CL. In solid-phase assays, L2GPI
increased, preferentially, the binding of low-avidity autoimmune aPL to CL but inhibited the binding of low-avidity syphilitic
aPL. In the absence of L2GPI, both autoimmune and infectious aPL induced the leakage of the entrapped fluorescent probe,
carboxyfluorescein (CF), from small unilamellar vesicles containing CL. aPL-induced probe leakage was protein
concentration-dependent and characterized by a lag-phase onset of 100^120 min. L2GPI increased the leakage rate induced
by low-avidity autoimmune aPL only and inhibited the leakage induced by all syphilitic aPL. The following conclusions were
provided: (1) in the absence of L2GPI, autoimmune and infectious aPL bind to CL in a bilayer, inducing liposome leakage;
(2) the leakage mechanism induced by aPL is suggested to be intravesicular ; (3) L2GPI requirement for phospholipid binding
in both solid and fluid phase is associated to aPL avidity; (4) CL alone or the CL^L2GPI complex are the most likely epitopes
for autoimmune aPL; (5) aPL from syphilis patients can only form the CL^aPL complex, supporting that L2GPI is not (part
of) the target epitope. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Antiphospholipid antibodies (aPL) occur with high
frequency in autoimmune disorders such as systemic
lupus erythematosus (SLE) [1] and antiphospholipid
syndrome (APS) [2], in infectious diseases (syphilis)
[3], and following some drug treatments [4,5]. Severe
clinical complications such as venous and arterial
thrombosis [6], thrombocytopenia [7] and intrauter-
ine fetal death [8,9] are currently associated with
autoimmune aPL, but not with aPL detected in syph-
ilis patients. However, a high prevalence of aPL in
patients with hepatitis C virus (HCV), in asympto-
matic infection, has also been associated with throm-
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bocytopenia, a history of thrombotic episodes and
portal hypertension [10,11]. The pathogenesis and
clinical signi¢cance of these autoantibodies remain
unclear regardless that aPL are considered a family
of related antibodies but with distinct properties [12].
A solid-phase immunoassay (ELISA), using cardi-
olipin (CL) as antigen, has been widely adopted for
detection of aPL in patient sera [13]. The use of
bovine serum as a sample diluent enhances the bind-
ing of aPL to target phospholipid [14,15]. This ob-
servation was rationalized by independent reports
showing that a plasma protein, L2-glycoprotein I
(L2GPI), plays a critical role in the binding of aPL
to CL. A requirement of L2GPI for autoimmune aPL
binding to CL was observed, suggesting that aPL
may bind to antigens shared by CL and L2GPI
[16]. It was also suggested that L2GPI, rather than
CL, was the target antigen for aPL from autoim-
mune disorders [17^19]. L2GPI requisite for aPL
binding was variable depending on the disease
[20,21]. However, negatively charged phospholipid
alone is still proposed as a potent target epitope
for aPL [22^24]. Although active animal immuniza-
tion studies have shown that CL alone does not in-
duce aPL production, liposomes containing various
lipids (cholesterol, dicetylphosphate, dipalmitoyl-
phosphatidylcholine and lipid A) induced aPL pro-
duction [25,26]. Immunization with human delipid-
ated (or not) L2GPI induces both aPL and anti-
L2GPI antibodies [27^29], generating an animal mod-
el for antiphospholipid syndrome [30]. In contrast to
autoimmune aPL, aPL from syphilis bind to CL in
the VDRL (Veneral Disease Research Laboratories)
antigen containing CL, phosphatidylcholine (PC)
and cholesterol, and exhibit little cross-reactivity
with other negatively charged phospholipids [31,32].
The binding of infectious aPL to CL-coated ELISA
plates is inhibited by L2GPI [33,34]. These observa-
tions summarize some of the present controversies
about the nature of the antigen responsible for aPL
reactivity.
Although the precise physiological role remains
obscure, L2GPI is known to: (a) be associated with
lipoprotein structures, especially chylomicrons [35],
(b) bind to platelets and heparin [36], and (c) bind
to negatively charged phospholipids [37]. L2GPI has
been reported to inhibit both platelet prothrombi-
nase activity [38] and ADP-induced platelet aggrega-
tion [39]. Some of the known properties of L2GPI
and aPL relate both proteins to the pathogenesis of
thrombosis in autoimmune disorders. Thrombi in-
duced in the femoral veins of CD-1 mice were sig-
ni¢cantly larger and persisted longer in mice with
aPL, independently of the production (or not) of
anti-L2GPI antibodies [23]. Because L2GPI inhibits,
in vitro, the contact activation system in blood coag-
ulation, blocking of L2GPI hemostatic response by
aPL might predispose to thrombosis [40]. A⁄nity-
puri¢ed IgG anticardiolipin antibodies from APS pa-
tients also inhibit the prothrombin^thrombin conver-
sion reaction [41]. Protein C activation is inhibited by
aPL predisposing to thrombosis [42]. It has also been
shown that the binding of L2GPI to PS on apoptotic
cells is essential in mediating the immunophysiologic
clearance of senescent non-self particles [43]. A dys-
function in the apoptotic process could create neo-
epitopes that then would stimulate the production of
natural aPL. Therefore, the binding of L2GPI and
aPL to phospholipids interferes with coagulation
and apoptotic pathways, though the mechanism(s)
that induce the clinical features remain to be ascer-
tained.
Despite progressing comprehension about the in-
teraction of the complex CL^L2GPI^aPL, the molec-
ular details of antigen^antibody association in £uid
phase remains obscure. Under various pathological
circumstances, phospholipids in bilayers are prob-
ably present in microparticles or cell fragments cir-
culating in vivo. Under this approach, phospholipid
liposomes have been used as models for examining
the interactions of lipids with various limbs of the
immune system [44]. Small unilamellar vesicles are
ultimate model systems to study lipid^protein inter-
action in £uid phase. First, lipid composition of SUV
are e¡ortlessly manipulated and de¢ned. Thus, fac-
tors like surface charge, lipid head group speci¢city
and membrane £uidity can be considered. Second,
the sonication procedure generates stable liposomes
that are essentially unilamellar, allowing the determi-
nation of several e¡ects induced by protein^vesicle
interaction. In order to study the interaction of
aPL with negatively charged phospholipids in an ap-
propriate and emblematic bilayer in £uid phase, we
selected CL-containing liposomes as a model for the
phospholipid antigen presentation. Both aPL from
autoimmune diseases (such as SLE and APS) and
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from infectious diseases (such as syphilis) induced the
leakage of entrapped carboxy£uorescein from lipo-
somes [45]. However, a great number of studies
used either the sera or polyclonal aPL which possibly
contain L2GPI contamination. Here we investigated
the interaction of puri¢ed aPL, assuredly L2GPI-free,
to CL-containing vesicles and associated the L2GPI
requirement for the aPL binding to CL with aPL
apparent avidity. In addition, we examined the ef-
fects of added puri¢ed human L2GPI on the aPL^
vesicle interaction. We demonstrated that both aPL
from autoimmune and infectious diseases induce the
leakage of internal contents of CL-containing lipo-
somes in the absence of L2GPI. For aPL from auto-
immune diseases, antibody avidity to CL is directly
associated with L2GPI requirement for e⁄cient inter-
facial recognition or binding to CL in £uid phase. In
contrast, L2GPI inhibit the leakage rate induced by
infectious aPL, independently of aPL avidity. The
leakage mechanism induced by aPL is discussed.
2. Materials and methods
2.1. Chemicals
Cardiolipin from bovine heart, phosphatidyletha-
nolamine (PE), phosphatidylserine (PS), phosphati-
dylinositol (PI), phosphatidylglycerol (PG), phospha-
tidic acid (PA), bovine serum albumin (BSA), adult
bovine sera (ABS), Tris bu¡er, phosphate-bu¡ered
saline (PBS), Triton X-100, alkaline phosphatase-
conjugated goat anti-human immunoglobulin, and
p-nitrophenylphosphate were all purchased from Sig-
ma Chemical Co. (St. Louis, MO). Egg PC was pu-
ri¢ed as described [46]. 6-Carboxy£uorescein (CF)
from Eastman Kodak Co. (New York, NY) was pu-
ri¢ed chromatographically [47]. All other chemicals
were of analytical grade or better from regular com-
mercial sources. Flat-bottom 96-well microtitration
plates were obtained from ICN Biomedicals (Aurora,
OH).
2.2. Patient sera
Ten sera from APS and SLE patients (following
ACR criteria) were selected for study for being pos-
itive in anticardiolipin ELISA tests [13]. Sera from
¢ve patients with syphilis diagnosed on the basis of
reactivity by VDRL and Treponema antibody-ab-
sorption (FTA-ABS) tests were evaluated. Sera
from 10 healthy donors were used as negative con-
trols.
2.3. Puri¢cation and characterization of IgG fractions
of aPL
Antiphospholipid antibodies of the IgG isotype
were isolated from human serum by protein G-Se-
pharose 4B a⁄nity chromatography (Pharmacia)
[48]. IgG fractions were eluted with 2% acetic acid,
immediately neutralized with 1% (v/v) 2.5 M Tris
(pH 8) and dialyzed against 0.1 M NaCl/10 mM
Tris (pH 7.2). As a second puri¢cation step, IgG
fractions were applied to Sepharose^heparin CL-6B
fast-£ow (Pharmacia) which retains contaminant
L2GPI. IgG fractions were recuperated in the column
£ow through and dialyzed against PBS, fractionated
and frozen. All procedures were developed at 4‡C.
IgG isotype and purity was established by SDS^poly-
acrylamide gel electrophoresis. Protein concentration
was controlled by absorbance measurements at
280 nm.
2.4. L2GPI puri¢cation
L2GPI was puri¢ed by a modi¢cation of the tech-
nique described in [49]. Brie£y, human healthy serum
was treated with perchloric acid (2.9% v/v) at 4‡C.
The mixture was stirred for 30 min and centrifuged
at 10 000 rpm for 30 min at 4‡C. The supernatant
was neutralized to pH 6^7 with saturated sodium
carbonate and dialyzed against 0.03 M NaCl/20
mM Tris (pH 7.1^7.2). L2GPI was obtained by Se-
pharose^heparin CL-6B fast-£ow (Pharmacia) a⁄n-
ity chromatography at 4‡C, using 0.35 M NaCl/20
mM Tris (pH 8.5) to elute the protein. Puri¢ed
L2GPI was dialyzed against PBS (pH 7.4) and pro-
tein concentration was measured according to Mor-
ton [50].
2.5. Dot-blot immunoassay
Two Wl of 0.5 mg/ml puri¢ed IgG-aPL were spot-
ted onto 0.45-Wm nitrocellulose membranes (Bio-Rad
Laboratories, Hercules, CA) and dried at room tem-
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perature (24 þ 1‡C). Membranes were shaken in the
blocking bu¡er (5% non-fat dry milk, 0.1% Tween-
20, PBS, pH 7.4) for 45 min, washed with PBS for 10
min and then incubated with a 1:5 dilution in PBS of
the yeast culture supernatant containing monoclonal
anti-L2GPI (A.E. Gharavi, in preparation) for 90
min under continuous agitation. Membranes were
washed ¢ve times with PBS for 5 min, and incubated
for 90 min with alkaline-phosphatase conjugated
goat anti-mouse IgG (whole molecule) (Sigma) di-
luted 1:3000 in PBS. Membranes were washed ¢ve
times with PBS for 5 min. Color development was
visualized after incubation of membranes with the
substrate solution (NTB and BCIP from Promega,
Madison, WI). After positive spot development for
the L2GPI standard curve, membranes were dipped
into distilled water to stop the reaction. The whole
procedure was performed at room temperature
(24 þ 1‡C).
2.6. Enzyme-linked immunosorbent assays (ELISA)
for aPL
The method for detecting aPL in ELISA was per-
formed as described [48]. Brie£y, ELISA plates were
coated overnight at 4‡C with 30 Wl/well of 0.05 mg/
ml CL in ethanol (or in methanol/chloroform 3:1 v/v
for other phospholipids). The plates were blocked
with 2% BSA/PBS for 60 min at 4‡C. Appropriated
amount of IgG was diluted in 10% ABS/PBS for the
experiments in the presence of L2GPI or in 2% BSA/
PBS for those in the absence of L2GPI, and incu-
bated for 150 min at 4‡C. Goat anti-human IgG (Q
chain) alkaline phosphatase-conjugated antibody was
applied for 1 h at 4‡C and plates were developed
with p-nitrophenylphosphate. Optical density (OD)
was read at 405 nm in a Titertek ELISA reader.
2.7. Avidity
Avidity of IgG-aPL to CL on solid phase was
estimated by ELISA by inhibition of aPL binding
to CL by ionic strength increase [51,52]. The ELISA
procedure was similar to that described above, modi-
¢ed by increasing NaCl concentrations added to the
blocking step (2% BSA/PBS) and to the sample dilu-
tion (10% ABS/PBS), and in the washing bu¡er
(PBS) within these steps.
2.8. Preparation and puri¢cation of the vesicles
Vesicle preparation method was slightly modi¢ed
from a previously published technique [45,47].
Brie£y, CL and PC dissolved in ethanol were evapo-
rated under nitrogen and dried for 60 min under
vacuum. The lipid ¢lm was resuspended in 10 mM
Tris (pH 7.4) containing 0.05 M CF. The dispersion
was sonicated using a Sonicator Virsonic 300 (Virtis
Co., Gardiner, NY) equipped with titanium tip (iced
bath, 1 min at 40% full power, 1 min o¡ for eight or
more cycles until transparency). The sonicated prep-
aration was then centrifuged for 60 min at 15 000
rpm. Non-entrapped CF was removed from CF-con-
taining vesicles by Sephadex G-25 ¢ne ¢ltration
(Pharmacia) [45,47]. The ¢nal applied lipid concen-
tration was 4.0 þ 0.5 WM, measured by phosphorus
analysis [53].
2.9. Leakage from the intravesicle water compartment
CF, encapsulated within the vesicles at the highly
self-quenching concentration, allows continuous
monitoring of marker release from the vesicles [47].
The release of water-soluble vesicle contents after
mixing aPL and/or L2GPI with vesicles (always latest
added) was evaluated by the increased CF £uores-
cence released into the milieu (0.47 M sucrose/10
mM Tris, pH 7.4). Fluorescence intensity was moni-
tored with time (excitation at 490 nm, emission at
520 nm) in a 650-15 spectro£uorimeter (Perkin
Elmer). To calculate the percent of CF leakage,
the £uorescence of residual CF was taken as
F0 and the total £uorescence intensity, Ft was ob-
tained from total vesicle lysis with Triton X-100
(0.5% v/v):
%CF  fF3F0=Ft3F0gU100 1
where F is the £uorescence intensity at any time [45].
Vesicles were stable and spontaneous leakage of CF
did not exceed 10% over the course of the experi-
ments.
2.10. Static light scattering (SLS)
The radius of gyration (Rg) was obtained by static
light scattering using a Dawn-F multiangle scattering
photometer (Wyatt Instruments, Santa Barbara, CA)
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[54]. The average Rg of the vesicles used here was
40 þ 20 nm.
3. Results
3.1. Puri¢cation of IgG isotype APL from patient
sera
From patient sera with autoimmune or infectious
diseases, we puri¢ed the aPL by standard procedures
to obtain IgG isotype antibodies [48]. It was essential
to determine L2GPI contents in the puri¢ed IgG-aPL
samples. To measure the L2GPI contamination in the
aPL samples we used a dot-blot assay adapted from
the Western-blot technique which was sensitive to
1 ng/ml of L2GPI. A monoclonal anti-L2GPI anti-
body was applied for protein quanti¢cation (for
details see Section 2). IgG-aPL samples puri¢ed
only by protein G-Sepharose column contained ca.
100 ng L2GPI per Wg of IgG-aPL (Fig. 1, lane 2),
emphasizing the need of a second puri¢cation step.
In order to eliminate L2GPI contamination, the pre-
treated IgG-aPL samples were applied to a Sephar-
ose^heparin column. By dot blot, we demonstrated
that IgG-aPL puri¢ed here contained less than 1 ng
of L2GPI per Wg of IgG-aPL (Fig. 1, lane 3). The
same BSA used for the ELISA blocking steps was
applied as negative control in the dot blot, revealing
no L2GPI contamination (data not shown). Accord-
ing to previous studies, the minimum L2GPI concen-
tration required to act as a cofactor for the auto-
immune aPL binding to CL is 0.5^1.0 Wg/ml L2GPI
per 70^100 Wg/ml IgG-aPL, which was certainly not
reached here due to L2GPI contamination [48].
Fig. 1. L2GPI detection by dot blot. Protein concentrations es-
tablished on the left side represent human puri¢ed L2GPI con-
centration applied as standard (column named L2GPI) or the
applied IgG-aPL concentration (columns 1 and 2). L2GPI con-
tamination was analyzed in aPL puri¢ed by Sepharose^protein
G chromatography (lane 1) or by Sepharose^protein G fol-
lowed by heparin^Sepharose chromatography (lane 2).
Fig. 2. Apparent antiphospholipid antibody avidity estimated
by ELISA. Serial dilutions of puri¢ed IgG-aPL were applied to
ELISA plates in the presence of increased salt concentrations
(NaCl) in the diluent bu¡er (10% ABS/PBS) as described in
Section 2. Representative patient with autoimmune disease
showing high (A) or low (B) avidity to CL and a representative
patient with syphilis shows low avidity to CL (C). b, 15 Wg/ml
IgG-aPL; F, 30 Wg/ml IgG-aPL; R, 60 Wg/ml IgG-aPL.
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3.2. Apparent antibody avidity
The summation of attractive and repulsive forces
involved in the interaction between an antigenic de-
terminant and the homologous antibody combining
site represents the antibody a⁄nity. Antibody avid-
ity, on the other hand, depends in part on a⁄nity,
but also involves other factors associated to binding
such as antibody valency and electrostatic forces
[51,52]. Because electrostatic forces govern the aPL
binding to negatively charged phospholipid, we eval-
uated the apparent avidity of IgG-aPL by ELISA
using increasing ionic strength as inhibitor agent
for the IgG-aPL binding to CL. Fig. 2 shows the
pro¢le of signi¢cant IgG-aPL from an autoimmune
patient of considered high- (Fig. 2A) and low-avidity
(Fig. 2B) antibody and one representative pro¢le of
IgG-aPL from syphilitic patients (Fig. 2C). Three of
10 puri¢ed autoimmune aPL-IgG maintained similar
OD values in the presence of 0.3 M salt and the
IgG-aPL binding capacity to CL was inhibited only
15^20% by the addition of 1 M salt (Fig. 2A: 60 Wg/
ml IgG). The observed high association of the anti-
gen^antibody complex distinguished these antibodies
to be classi¢ed as high-avidity aPL in this study. For
the other seven autoimmune IgG-aPL samples, 0.3 M
salt, only double the salt concentration of the phys-
iological milieu, inhibited 40% to 60% of aPL-bind-
ing capacity to CL (Fig. 2B). This percentage of in-
hibition, associated with no detectable aPL-binding
at 0.6 M NaCl, de¢ned the characteristic pro¢le of
low avidity aPL. All ¢ve aPL samples from patients
with syphilis showed a low-avidity pro¢le (Fig. 2C).
Table 1 shows the general classi¢cation of the aPL
samples according to CL avidity in the presence of
L2GPI.
The ELISA binding curves consist of a phase pla-
teau at low antibody dilutions followed by a steep
fall at high dilution that di¡erentiates high- and low-
a⁄nity antibodies [52]. In order to con¢rm the pre-
vious avidity classi¢cation, we measured the CL-
binding of all puri¢ed aPL within 10 to 100 Wg/ml
Table 1
Apparent avidity associated to L2GPI requirement for aPL binding to CL in solid phasea
Sample Without L2GPIa With L2GPIa Sloped Interceptd Apparent aviditye
Blankb 0.08 0.090 ^ ^ ^
Negativec 0.21 0.10 ^ ^ ^
1. MH 1.24 1.31 0.0047 1.144 High
2. GB 1.18 1.30 0.0042 1.078 High
3. AR 0.95 1.09 0.0039 1.005 High
4. GP 0.45 0.75 0.0087 0.349 Low
5. WY 0.31 0.65 0.0114 0.170 Low
6. PT 0.52 0.72 0.0161 0.236 Low
7. AD 0.28 0.63 0.0102 0.185 Low
8. DZ 0.50 1.25 0.0071 0.486 Low
9. EA 0.26 0.46 0.0062 0.066 Low
10. NK 0.23 0.60 0.0101 0.232 Low
11. B5 0.50 0.35 0.0057 0.0124 Low
12. B16 0.59 0.25 0.0058 30.0410 Low
13. B19 1.31 0.20 0.0018 30.0021 Low
14. B20 0.24 0.06 0.0038 30.0367 Low
15. B22 0.75 0.35 0.0065 0.0193 Low
aaPL puri¢ed from 10 patients with autoimmune diseases (samples 1^10) and from ¢ve patients with syphilis (samples 11^15) were ap-
plied to CL-coated ELISA plates and the OD values in the absence and presence of L2GPI are shown.
b‘Blank’ refers to OD values obtained in the absence of sera (substituted by bu¡er) that were already subtracted from the OD values
presented for each sample above.
c‘Negative’ refers to OD values obtained by the average of 10 healthy donor-puri¢ed IgG antibodies.
dA serial dilution of puri¢ed IgG-aPL from each patient was tested for binding to CL in solid phase in the presence of L2GPI. The
slope and intercept values from the plot of puri¢ed IgG-aPL concentration versus the respective OD values for each patient are pre-
sented.
eSamples were classi¢ed as high- or low-avidity aPL samples according to the apparent avidity to CL in the ELISA assays.
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of IgG concentration range by standard ELISA (0.15
M salt). OD values were proportional to the IgG-
aPL dilution only in the case of low-avidity antibod-
ies (compare di¡erent symbols at 0.15 M NaCl in
Fig. 2). Every plot of IgG concentration by OD
was linear, and the calculated slope and intercept
for each curve is presented in Table 1. The intercept
values are coincident with the OD value at the long
phase plateau before the steep fall dilution point,
which increases with low-avidity syphilitic aPL6 au-
toimmune low-avidity aPL6 autoimmune high-avid-
ity aPL, respectively (Table 1). No notable changes
are observed in the slope values among all aPL.
3.3. L2GPI requirement for IgG-aPL binding to CL
in ELISA
Although it is commonly accepted that L2GPI af-
fects aPL binding in CL-ELISA tests, there is contra-
dictory data about aPL binding to CL in the absence
of L2GPI [12,16,22]. As indicated in Fig. 3, L2GPI-
free IgG-aPL bound to CL in the absence and pres-
ence of L2GPI. Three autoimmune high-avidity aPL
presented high OD values, demonstrating stronger
binding to CL in the absence of L2GPI (Fig. 3A).
All seven autoimmune low-avidity aPL bound to
CL in the absence of L2GPI (Fig. 3B) but much high-
er IgG-aPL concentrations (s 80 Wg/ml) were re-
quired to clearly distinguish a positive aPL binding
from negative binding due to non-speci¢c normal
IgG antibodies. Taken together, these data con¢rm
the binding of IgG-aPL to CL in the absence of
L2GPI, disassociated from aPL avidity. Table 1
shows the OD values obtained in the absence and
presence of L2GPI for aPL bound to CL. Our data
showed a larger L2GPI requirement for low-avidity
aPL than for high-avidity aPL, which is in entire
agreement with previous reports [48]. In addition,
L2GPI inhibited the CL-binding of aPL from syphilis
patients (Table 1).
3.4. aPL binding to negatively charged phospholipids
by ELISA
In order to investigate a possible association of
aPL avidity with binding to several negatively
charged phospholipids, all samples were tested for
binding to PS, PA, PI, PE, and PC by ELISA in
the presence of L2GPI. In the absence of internation-
al standards for non-cardiolipin antibodies, we used
as a cut-o¡ value that of the mean OD from 10
negative controls (0.14 þ 0.06) plus 3 standard devia-
tions. Thus, aPL binding to phospholipids was con-
sidered positive for those samples originating
ODs 0.32. All 10 autoimmune IgG-aPL samples
bound to CL and PA in the standard ELISA.
Among the autoimmune IgG-aPL samples, 70%
(n = 7) were positive for binding to PS, 10% (n = 1)
for PG and 70% (n = 7) for PI. No autoimmune aPL
presented signi¢cant binding to PE or PC. Among
the syphilitic samples, 20% (n = 1) were positive for
binding to PS, 60% (n = 3) for PA, 40% (n = 2) for
PG, 60% (n = 3) for PI. Although no signi¢cant bind-
ing to PE was detected, 80% (n = 4) of the aPL from
patients with syphilis recognized PC, a zwitterionic
phospholipid (data not shown). These data con¢rm
that the binding capacity of aPL to negatively
charged phospholipids is higher for aPL from auto-
immune than infectious disorders in solid-phase as-
says [3,14,32,34]. No pattern relating aPL avidity
with lipid binding speci¢city was evident from these
assays.
3.5. Membrane^protein interaction assay based on
£uorescent probe leakage
To examine whether aPL from autoimmune dis-
Fig. 3. Autoimmune aPL binding to cardiolipin in solid-phase
assay (ELISA). Plot of the OD values obtained due to increas-
ing concentrations of puri¢ed IgG-aPL in the absence (open
symbols) or presence (full symbols) of L2GPI. Three high-avid-
ity aPL (MH, GB and AR) pro¢les (A) are compared with two
representative low-avidity aPL (GP and WY) pro¢les (B). b,
IgG GB; F, IgG MH; h, IgG AR; R, IgG GP; S, IgG WY;
8, IgG from healthy donors.
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eases can interact with CL in a well-de¢ned bilayer in
solution, we used CL-containing vesicles with en-
trapped carboxy£uorescein (CF). A⁄nity-puri¢ed
IgG-aPL were incubated with CF-containing CL/
PC vesicles in a salt-free bu¡er with 0.47 M sucrose
to keep the osmotic pressure balance. Incubation of
vesicles and aPL at 22 þ 1‡C produced an extremely
slow leakage with no signi¢cant di¡erence between
the leakage induced by IgG-aPL and by IgG from
healthy donors (data not shown). Upon incubation
at 29 þ 1‡C, IgG-aPL induced remarkable CF leak-
age from vesicles containing either 20 mol% or 50
mol% CL. Fig. 4 shows the CF release kinetics for
low- and high-avidity aPL provided from patient
sera with SLE. A similar kinetic pro¢le was induced
by aPL from patient sera with syphilis (Fig. 6). A
peculiar incubation lag phase extending up to 150
min was detected for all IgG-aPL. The lag phase
was not discontinued by increasing autoimmune or
infectious aPL concentrations (Fig. 4) or increasing
CL contents in the membrane (data not shown). In-
cubation of aPL with vesicles containing 100% PC
did not induce changes in the £uorescence intensity,
con¢rming the speci¢c aPL binding to CL (data not
shown). These results demonstrate that L2GPI-free
IgG-aPL from autoimmune and infectious diseases
interact with CL bilayers in solution, inducing the
leakage of CL vesicles. This phenomenon is inde-
pendent of the aPL avidity to CL.
It is acclaimed that L2GPI binds to negatively
charged phospholipids in multilamellar vesicles [37].
In order to investigate whether L2GPI alone induces
leakage from unilamellar vesicles, human puri¢ed
L2GPI was incubated with CF-containing CL/PC
vesicles. At 22 þ 1‡C, no leakage was observed before
4 h incubation. At 29 þ 1‡C, 1 to 10 Wg/ml L2GPI
induced time-dependent CF release from vesicles
containing CL/PC (1:4 mol%). The leakage rate
was dependent on L2GPI concentration (data not
shown). Similar results were obtained with higher
CL molar ratios (1:1 mol% CL/PC), although lower
L2GPI concentrations were required for a similar
Fig. 5. L2GPI e¡ect in the kinetics of carboxy£uorescein (CF) release from CL/PC (1:1 molar) vesicles induced by autoimmune aPL.
Vesicles were incubated with 10 Wg/ml IgG-aPL in the absence (open symbols) or presence (full symbols) of 10 ng/ml of L2GPI at
29 þ 1‡C. Although the kinetics pro¢le induced by apparent high-avidity autoimmune aPL was invariable (R, IgG MH; 8, IgG GB)
(A), the presence of L2GPI increased the kinetic rate induced by apparent low-avidity autoimmune aPL (b, IgG GP; F, IgG WY)
(B). P, 10 ng/ml L2GPI; k, 10 Wg/ml IgG from healthy donors in the presence of L2GPI.
Fig. 4. Kinetics of carboxy£uorescein (CF) release from CL/PC
(1:1 molar) vesicles induced by puri¢ed IgG-aPL. Autoimmune
L2GPI-free aPL were incubated with the vesicles in the absence
of L2GPI at 29 þ 1‡C. Apparent high-avidity (full symbols) and
low-avidity (open symbols) autoimmune aPL revealed similar
kinetics pro¢les that completely diverge from the pro¢le in-
duced by IgG puri¢ed from healthy donors (k). Symbols rep-
resent puri¢ed aPL from di¡erent patients.
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leakage pro¢le. Fig. 5 shows a representative kinetic
of CF release from CL/PC 1:1 vesicles induced by
10 ng/ml L2GPI. No CF leakage was noticed using
100% PC vesicles. These results indicated that L2GPI
itself binds to CL vesicles in £uid phase, inducing the
leakage of the vesicle contents.
3.6. L2GPI requirement on aPL binding to
CL-containing vesicles
Because both puri¢ed aPL and L2GPI induce the
leakage of vesicle contents, we investigated whether
L2GPI a¡ected aPL-induced vesicle leakage (Fig. 5).
Resulting vesicle leakage induced by aPL due to
L2GPI addition was dependent on the origin of
aPL. In the case of autoimmune aPL, the leakage
rate induced by low-avidity aPL increased upon ad-
dition of low concentrations of L2GPI (Fig. 5A). The
lag phase decreased from 240 min (considering 1 ng/
ml L2GPI only) or from 150 min (considering 10 Wg/
ml aPL only) to 100^110 min on vesicles exposed to
both L2GPI and aPL (Fig. 5B) considering CL/PC
1:1 vesicles at 29 þ 1‡C. Similar e¡ects were observed
for all seven low-avidity aPL, using vesicles with 20%
or 50% CL at 29 þ 1‡C (data not shown). In contrast,
vesicle leakage induced by high-avidity aPL was not
a¡ected by the presence of L2GPI (Fig. 5A), not even
for the high-avidity aPL (patient GB in Fig. 5A) that
showed increase in binding to CL induced by L2GPI
addition in the ELISA assay (Fig. 3A). These data
show that aPL avidity is related to L2GPI require-
ment for CL-binding in solution. On the contrary,
puri¢ed L2GPI inhibited the CF release induced by
all ¢ve puri¢ed aPL from patients with syphilis (Fig.
6), at 20% or 50% CL/PC vesicles. The kinetics pro-
¢le for syphilitic aPL obtained in the presence of
L2GPI, for 60% of the samples (3/5), achieved the
same rate as that induced by L2GPI alone (Fig. 6).
3.7. Light-scattering measurements
Protein binding to phospholipid vesicles can result
in a membrane defect, vesicle aggregation or vesicle
fusion ([55,56] and references therein). The last two
phenomena commonly result in increase of vesicle
size or aggregate. We monitored vesicle size (radius
of gyration) by SLS to verify whether the internal
content leakage induced by aPL was due to vesicle
fusion or aggregation. No changes in the hydrody-
namic radius of CL/PC vesicles with bound aPL were
detected through time, suggesting that the recorded
leakage induced by aPL was due to the aPL binding
to CL in a single vesicle.
4. Discussion
The role of L2GPI in the binding of aPL to anionic
phospholipids has certainly provoked intense re-
search in the aPL ¢eld, regarding L2GPI as either
cofactor for the phospholipid binding or being
(part of) the epitope itself. A vast majority of these
studies used solid-phase assays, a technique that may
not be providing the closest phospholipid arrange-
ment to that existent in vivo. Here we report new
aspects of the interaction of the target epitope and
aPL from infectious and autoimmune disorders using
a biomimetic model and strictly puri¢ed proteins. We
demonstrated that aPL from autoimmune or infec-
tious disorders interact with CL in solid or £uid
phase in assured absence of L2GPI. The evaluation
of aPL apparent avidity demonstrated that L2GPI
requirement for binding to CL is: (1) associated to
Fig. 6. L2GPI e¡ect on the kinetics of carboxy£uorescein (CF)
release from CL/PC (1:1 molar) vesicles induced by aPL from
syphilis. Vesicles were incubated with 10 Wg/ml IgG-aPL in the
absence (open symbols) or presence (full symbols) of 10 ng/ml
of L2GPI at 29 þ 1‡C. L2GPI inhibited the leakage rate induced
by aPL from all syphilis patients (di¡erent symbols), reaching
the basal rate induced by healthy donors in the presence of
L2GPI (k).
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aPL avidity to CL and (2) opposite to the aPL
pathological origin (infectious or autoimmune).
The binding of L2GPI-free aPL to CL was ¢rst
evaluated when CL was presented in a solid-phase
assay. We demonstrated that L2GPI-free puri¢ed
IgG-aPL from autoimmune and infectious disorders
bind to CL in ELISA assays. The aPL^CL binding is
dependent on aPL concentration and aPL avidity to
CL. Approximately 10 Wg/ml of IgG-aPL were
enough to distinguish high-avidity aPL from normal
IgG in a modi¢ed ELISA assay. However, higher
concentrations of low-avidity aPL (s 80 Wg/ml) are
required to distinguish positive aPL binding to CL
from the non-speci¢c binding of IgG from normal
controls. These results may explain particular contro-
versies when no detectable aPL binding to CL in the
absence of L2GPI was noticed by ELISA, likely be-
cause of the appliance of low IgG concentrations
(4 Wg/ml [16], 17 Wg/ml [17], 8^23 Wg/ml [57]).
We detected the binding of very low concentra-
tions of aPL puri¢ed from three di¡erent autoim-
mune patients, suggesting the existence of high-avid-
ity antibodies (Table 1) [52]. Indirect competition
ELISA assay, a convenient method for estimating
antibody a⁄nity, was based on the electrostatic in-
teractions among aPL^CL^L2GPI to evaluate aPL
avidity [58]. The characterization of the strength of
antigen^antibody interaction distinguished aPL in
two groups: high- or low-avidity aPL. Patients with
syphilis presented exclusively low-avidity aPL. How-
ever, 30% of the patients with autoimmune disorders
presented high-avidity aPL. Other infectious disor-
ders, like malaria and AIDS, have also been associ-
ated to the presence of low-avidity aPL, when avidity
was compared to autoimmune aPL features [59].
These data suggest a possible association between
aPL pathological origin and its avidity, also likely
to be associated with thrombosis in autoimmune
aPL but not in infectious diseases. However, further
studies are required to clearly correlate thrombosis
origin in autoimmune disorders. Therefore, measure-
ments of apparent aPL avidity may be of substantial
value for subsequent aPL studies as well as on pa-
tient care.
In light of several reports showing the binding of
antibody to L2GPI in the absence of phospholipid,
we tested the binding of all puri¢ed aPL to L2GPI by
ELISA [17^19,57]. Particularly two of three autoim-
mune high-avidity puri¢ed aPL bound to L2GPI pre-
sented in solid phase in the absence of additional
phospholipids (data not shown). This observation
suggests that the so-called high-avidity aPL are
anti-L2GPI antibodies. Due to inhibition of L2GPI
binding to negatively charged phospholipids by in-
creasing salt concentrations in the avidity assay,
L2GPI concentration should be decreasing at these
experimental conditions. If high-avidity aPL bind
speci¢cally to L2GPI, the detectable binding should
also decrease with increasing salt concentrations,
which was not veri¢ed. In addition, aPL from syph-
ilis patients did not bind to L2GPI in the absence of
phospholipids and the aPL binding to CL was inhib-
ited by increasing salt concentrations, in contrast to
the hypothesis that the autoantibodies studied here
could be anti-L2GPI antibodies. From another point
of view, these data suggest that aPL that recognized
the complex CL^L2GPI and L2GPI itself present a
higher a⁄nity binding than those aPL that bind
only to the complex.
We demonstrated that, in the absence of L2GPI,
puri¢ed IgG-aPL, from 10 di¡erent patients with
autoimmune disorders and ¢ve with syphilis, interact
to CL in a bilayer model, inducing the leakage of the
internal contents from the vesicles. In agreement with
aPL binding in the absence of L2GPI, puri¢ed aPL
from two patients with autoimmune diseases were
shown to bind in glass microspheres coated with
CL, PC and cholesterol [60]. Similar results were
reported using mouse aPL induced by liposomes con-
taining Lipid A [61].
We demonstrated, for the ¢rst time, that aPL in-
duce the leakage of the internal contents of CL-con-
taining vesicles. Interestingly, and consistent with
preceding reports [45], the lag phase for the probe
release onset was independent of IgG-aPL concentra-
tion, but strictly dependent on aPL avidity and
L2GPI concentration. Although high L2GPI concen-
trations (50 Wg/ml) decreased the lag phase, it was
not completely eliminated (data not shown). Increas-
ing CL vesicle contents did not a¡ect the lag phase,
indicating that CL density is not a factor that com-
pletely limits the leakage onset induced by aPL. In
addition, the aPL binding to CL-containing vesicles
did not enhance vesicle size. These ¢ndings strongly
suggest that the leakage induced by aPL is not a
consequence of vesicle aggregation or fusion. Based
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on similar experiments, we suggest that the vesicle
content leakage induced by L2GPI alone is not due
to fusion or aggregation of the vesicles.
Antibody binding to phospholipids in solid-phase
assays is temperature dependent [62]. IgG-aPL bind-
ing to CL bilayer was also notably sensitive to tem-
perature; in particular the lag-phase span for vesicle
leakage decreased from 400^500 min at 22 þ 1‡C to
120^150 min at 29 þ 1‡C. Increasing temperature al-
ters membrane £uidity from gel to £uid phase, pro-
viding more phospholipid mobility [63]. The straight
dependence of CL mobility for aPL binding, either in
solid or £uid phase, suggests that aPL detain more
than one molecule of CL in the lipid-binding site.
Calculations of the relative size of one IgG binding
site and of one CL molecule suggested that eight CL
polar heads were required for complete interaction
[64]. These recordings indicate that local changes in
a single vesicle membrane structure occur upon anti-
body binding, implying that an intravesicular mech-
anism is responsible for vesicle content leakage in-
duced by aPL.
We analyzed the L2GPI cofactor activity in the
binding of aPL to CL in the £uid-phase model.
The mechanism analysis of vesicle leakage provided
evidence supporting a di¡erent epitope for autoim-
mune and infectious aPL. The probe leakage kinetic,
expressed by an apparent rate constant (kapp), is de-
pendent on the interaction of an antibody molecule
and a single probe-containing vesicle. In the case of
aPL from syphilitic patients, the binary aPL^vesicle
complex generates a higher kapp than the kapp repre-
senting the L2GPI^vesicle complex, since a higher
leakage rate is induced by syphilitic aPL than that
induced by L2GPI alone. However, from the analysis
of the vesicle leakage in the presence of both L2GPI
and syphilitic aPL, it can be conclude that kapp in-
duced by L2GPI is higher than kapp induced by aPL
due to the preponderance of the former over the
e¡ect induced by aPL alone. There is no formation
of the ternary vesicle^L2GPI^aPL complex in this
case, but competition between L2GPI and aPL for
the negatively charged surface, clearly demonstrated
that L2GPI is not part of the epitope recognized by
aPL from infectious diseases like syphilis. This phe-
nomenon is not dependent on aPL avidity and is in
good agreement with previous proposed epitopes for
syphilitic aPL [12,31,32]. In contrast, kapp induced by
high-avidity autoimmune aPL was apparently higher
than (or similar to) that induced by L2GPI alone,
since the addition of L2GPI did not substantially
alter the kapp induced by these aPL. In this case,
there was a preponderance of kapp induced by high-
avidity autoimmune aPL. For low-avidity autoim-
mune aPL, the L2GPI^aPL complex induced a higher
kapp than aPL or L2GPI by itself, suggesting the for-
mation of a ternary vesicle^L2GPI^aPL complex.
Although di¡erent kapp were induced by high- and
low-avidity autoimmune aPL, these ¢ndings con-
¢rmed that L2GPI is part of the epitope for (low-
avidity) autoimmune aPL.
Binding of aPL to its targets in vivo may be char-
acterized by a greater degree of complexity than in
vitro. In vivo targets of aPL identi¢ed to date include
monocytes [65], cultured HUVEC [66], surface of
activated platelets [67], and apoptotic cells [68]. The
binding of L2GPI to the newly exposed anionic phos-
pholipid on apoptotic cells is suggested to generate a
ligand by which apoptotic cells may be recognized by
macrophages for phagocytic clearance [68]. Thus, the
L2GPI^aPL complex formed on apoptotic cell sur-
face may contribute to the development of autoim-
munity by interfering with the normal cell clearance
and by the prominent autoantigens formed. This hy-
pothesis is supported by our results that distinctly
showed a stable complex aPL-lipid-L2GPI resistant
to high ionic strength. In addition, the lag phase
disclosed that the binding of aPL and/or L2GPI to
the vesicle outer surface is a prolonged process,
which is in accord with explanations of the origin
of the aPL antigen. The fact that infectious aPL do
not recognize L2GPI on a negatively charged surface
may also associate the thrombi formation in auto-
immune disorders with the L2GPI^aPL complex for-
mation [23].
In conclusion, we demonstrated that, in the ab-
sence of L2GPI, human puri¢ed IgG-aPL bind to
CL in solid-phase assay and to CL in a bilayer struc-
ture in £uid phase. Our data con¢rm the existence of
two di¡erent populations of autoimmune aPL. In
autoimmune diseases, L2GPI requirement for the
phospholipid binding is dependent on the apparent
avidity of the autoimmune aPL. Cardiolipin alone or
the complex CL^L2GPI are the most likely epitopes
for autoimmune aPL, CL alone, and certainly not
L2GPI, is the only epitope identi¢ed for infectious
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aPL. Further investigations are required to determine
the exact epitope for the di¡erent aPL populations
and the association with the clinical features of the
diseases.
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